

Press Release

Friday, April 25, 2014

Strides Arcolab Limited, Strides House, Bannerghatta Road, Bangalore – 560076, India

BSE: 532531 NSE: STAR

CONTINUED US FDA APPROVAL STATUS FOR ORAL DOSAGE FACILITY

April 25, 2014: Strides Arcolab is pleased to announce that its Oral Dosage Forms manufacturing site (KRS Gardens) in Bangalore was recently inspected by the USFDA as part of GMP compliance audit and the **facility continues to be approved.**

The last USFDA inspection and approval for this facility was in the year 2011.


The KRS Gardens facility in Bangalore manufactures oral dosage forms such as tablets, capsules (both hard gelatine and soft gelatine) and sachets. The manufacturing plant supports important current and future submissions for the US Market.

About Strides Arcolab

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical Company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products.

The Company has 5 manufacturing facilities presence in more than 75 countries in developed and emerging markets.

Additional information is available at the Company's website at www.stridesarco.com.



For further information, please contact:

Strides

Mr. Mohan Kumar, CEO – Pharma +91 80 6784 0748

Mr. Vikesh Kumar +91 80 6784 0827 Mr. Kannan. N: +91 98450 54745

PR Consultancy

Weber Shandwick

Kaveri Mandanna: +91 90089 59697 <u>KMandanna@webershandwick.com</u>

Mahesh Nair: +91 98803 76648 MNair@webershandwick.com

